Blue Square Asset Management LLC Reduces Position in Johnson & Johnson (NYSE:JNJ)

Blue Square Asset Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 16.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,871 shares of the company’s stock after selling 1,803 shares during the period. Johnson & Johnson makes up 1.3% of Blue Square Asset Management LLC’s portfolio, making the stock its 22nd biggest position. Blue Square Asset Management LLC’s holdings in Johnson & Johnson were worth $1,572,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Patron Partners LLC lifted its holdings in Johnson & Johnson by 12.7% in the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after acquiring an additional 747 shares during the period. Tandem Investment Advisors Inc. lifted its holdings in Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after acquiring an additional 15,003 shares during the period. Argent Advisors Inc. lifted its holdings in Johnson & Johnson by 6.6% in the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after acquiring an additional 1,218 shares during the period. Exeter Financial LLC lifted its holdings in Johnson & Johnson by 3.2% in the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after acquiring an additional 819 shares during the period. Finally, Winthrop Advisory Group LLC lifted its holdings in Johnson & Johnson by 3.7% in the first quarter. Winthrop Advisory Group LLC now owns 9,090 shares of the company’s stock valued at $1,611,000 after acquiring an additional 325 shares during the period. 68.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on JNJ. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. UBS Group decreased their price objective on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Morgan Stanley raised their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Credit Suisse Group raised their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Wells Fargo & Company raised their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Up 0.2 %

Shares of JNJ opened at $174.52 on Friday. The business’s 50 day moving average is $175.95 and its 200 day moving average is $174.42. The company has a market capitalization of $459.23 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 3.28 and a beta of 0.63. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.48 EPS. Research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.59%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.